Neoadjuvant chemo-immunotherapy for stage III PD-L1 positive Non-Small Cell Lung Cancer (NSCLC)

Conditions

stage III PD-L1 positive Non-Small Cell Lung Cancer (NSCLC)

Brief summary

Complete tumor resection rate (R0). An R0 resection means that the surgical margin is microscopically negative for residual tumor.

Detailed description

Percentage of nodal downstaging defined as following neoadjuvant chemoimmunotherapy, Pathological complete response (pCR) and major pathological response (MPR). pCR means 0% residual viable tumor cells in the primary tumor and sampled lymph nodes; MPR means ≤10% residual viable tumor cells in the primary tumor and sampled lymph nodes., Event-free survival (EFS) was defined as the time from study enrollment to any progression of disease before local treatment (surgery or radiotherapy) or recurrence of disease after local treatment (surgery or radiotherapy), progression of disease in the absence of surgery, or death from any cause., Overall survival (OS) was defined as the time from study enrollment to death of any cause

Related papers

No related papers found yet.

Interventions

DRUGTevimbra 100 mg concentrate for solution for infusion

DRUGCarboplatino Hikma 10 mg/ml soluzione per infusione

DRUGCisplatino Hikma 1mg/ml concentrato per soluzione per infusione

DRUGPaclitaxel Accord Healthcare Italia 6 mg/ml

DRUGconcentrato per soluzione per infusione

DRUGPemetrexed Ever Pharma 25 mg/ml concentrato per soluzione per infusione

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Secondary

Measure	Time frame
Percentage of nodal downstaging defined as following neoadjuvant chemoimmunotherapy, Pathological complete response (pCR) and major pathological response (MPR). pCR means 0% residual viable tumor cells in the primary tumor and sampled lymph nodes; MPR means ≤10% residual viable tumor cells in the primary tumor and sampled lymph nodes., Event-free survival (EFS) was defined as the time from study enrollment to any progression of disease before local treatment (surgery or radiotherapy) or recurrence of disease after local treatment (surgery or radiotherapy), progression of disease in the absence of surgery, or death from any cause., Overall survival (OS) was defined as the time from study enrollment to death of any cause	—

Measure

Time frame

Percentage of nodal downstaging defined as following neoadjuvant chemoimmunotherapy, Pathological complete response (pCR) and major pathological response (MPR). pCR means 0% residual viable tumor cells in the primary tumor and sampled lymph nodes; MPR means ≤10% residual viable tumor cells in the primary tumor and sampled lymph nodes., Event-free survival (EFS) was defined as the time from study enrollment to any progression of disease before local treatment (surgery or radiotherapy) or recurrence of disease after local treatment (surgery or radiotherapy), progression of disease in the absence of surgery, or death from any cause., Overall survival (OS) was defined as the time from study enrollment to death of any cause

—

Primary

Measure	Time frame
Complete tumor resection rate (R0). An R0 resection means that the surgical margin is microscopically negative for residual tumor.	—

Countries

Italy

Outcome results

None listed